RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial – Nature Medicine

Commentary on Twitter

The SURPASS-AP-Combo trial shows that addition of #tirzepatide as 2L or 3L therapy is non-inferior & superior to insulin glargine for glycemic outcomes at 40 weeks in an Asia-Pacific (mostly Chinese) population w/ type 2 #diabetes. https://t.co/RDh2WSJ1wZ pic.twitter.com/nm6pPpVdxH

— Nature Medicine (@NatureMedicine) June 2, 2023